Bristol-Myers Squibb (BMY) was downgraded today to a hold by thestreet.com's quantitative service. We have been positive on the charts and indicators for BMY - see our review of January 12 - where we recommended, "It has been months in the making but it looks like BMY is finally breaking out over the resistance in the $64-$66 area. Traders should stay long and consider increasing their exposure on strength above $67. Risk below $60 and $100 is our price objective for the first half of 2021."
More from Investing
You can't call this market overbought when so much of it isn't participating.
SKLZ shows explosion moves to the upside when it emerges from the oversold area.